Gene therapy co bags £80 million in Series B for kidney diseases drive

Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing.

The UK-based firm claims to be the first company to successfully treat kidney disease models by directly targeting the podocyte, a specialized cell implicated in approximately 60% of renal diseases, through its proprietary adeno-associated viral (AAV) gene therapy platform.

Purespring currently has a pipeline of programs in development. This includes its lead programPS-002, in development for IgA nephropathy (IgAN), and other complement-mediated kidney diseases, which targets nephrotic syndrome, and an undisclosed glomerular kidney disease program.